Cantor Fitzgerald initiated coverage of Design Therapeutics (DSGN) with an Overweight rating with no price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DSGN:
- Trump approves plan to fire FDA head Marty Makary, CBS reports
- Design Therapeutics price target raised to $21 from $18 at Oppenheimer
- Design Therapeutics price target raised to $20 from $12 at Piper Sandler
- Design Therapeutics reports Q1 EPS (29c), consensus (33c)
- Design Therapeutics Reports Q1 2026 Results and Pipeline Progress